David S. Hong, MD, on Outcomes of Larotrectinib in Patients with TRK Fusion Cancer
The medical oncologist discussed reported outcomes of larotrectinib in patients with TRK fusion cancer by the number of lines of priory therapy or baseline status.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
More News: Cancer | Cancer & Oncology